Tamir Biotechnology, Inc.   Report issue

For profit Phase 3
Founded: Monmouth Junction NJ United States (1981)
Status: Acquired by Orgenesis (2020)

Organization Overview

First Clinical Trial
1997
NCT00003034
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Alfacell

Active Ingredients

Drugs in Phase 3 Trials (2)

doxorubicin (Doxil) (1 trial)

ranpirnase (Onconase) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Condylomata Acuminata (Phase 2)

Lung Neoplasms (Phase 2)

Mesothelioma (Phase 3)

Papillomavirus Infections (Phase 2)

Sexually Transmitted Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2